NEA helps vascular repair firm Intact to $20M round

Intact Vascular's device (Intact Vascular)

Intact Vascular has raised $20 million to bring its postangioplasty dissection repair device to market. New Enterprise Associates (NEA) and other firms put up the money to see Intact through premarket approval of the Tack Endovascular System.

Wayne, Pennsylvania-based Intact designed the system to facilitate the repair of the dissections that can occur following balloon angioplasty. The percutaneous transluminal angioplasty (PTA) procedures used to treat peripheral artery disease can cause damage to vessels of varying degrees of severity. In some cases, the damage—dissection—is severe enough to restrict blood flow.

Intact thinks its system can treat such damage. The system features an over-the-wire delivery device loaded with self-expanding implants. Once the device reaches the site of a dissection, it drops off an implant, which expands to fill the diameter of the vessel.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Management at Intact think the approach will stop further narrowing of the artery, cut stress on the arterial wall, reduce the risk of acute arterial occlusion and otherwise improve outcomes.

NEA, H.I.G. BioVentures and Quaker Partners share Intact’s belief in the device. The investors joined together to commit $20 million to the company. Intact is pocketing the first tranche of money now, with a second set to follow later this year.

The financing sets Intact up to advance a clinical development program designed to generate data to support FDA approval of Tack. Intact is running three trials. The most advanced of the trials, which finished enrolling patients 13 months ago, is assessing the use of Tack in combination with plain and BARD Lutonix drug-coated balloon angioplasty.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.